Holen Sie sich die Stockscreener-App
27.55
1.08%
-0.30
Handel nachbörslich:
27.55
Schlusskurs vom Vortag:
$27.85
Offen:
$27.97
24-Stunden-Volumen:
1.73M
Relative Volume:
0.38
Marktkapitalisierung:
$3.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-29.62
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-6.16%
1M Leistung:
+19.26%
6M Leistung:
-59.77%
1J Leistung:
-65.65%
1-Tages-Spanne:
$27.45
$28.73
1-Wochen-Bereich:
$26.37
$29.73
52-Wochen-Spanne:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
27.55 | 3.30B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Why Viking Therapeutics (VKTX) Stock is Gaining Today - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - Yahoo
Viking Therapeutics (VKTX) Sees Unusual Options Activity | VKTX Stock News - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher In April - Barchart.com
Why Viking Therapeutics Stock Was Victorious This Week - MSN
(VKTX) Investment Report - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Sees 20% Stock Surge Despite Financial Losses - GuruFocus
Why Viking Therapeutics (VKTX) Stock is Rising Today - GuruFocus
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking Therapeutics (VKTX) Sees Surge in Call Options Trading | VKTX Stock News - GuruFocus
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025 - simplywall.st
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - The Globe and Mail
This Soaring Stock Just Delivered More Good News. Time to Buy? - AOL.com
Where Will Viking Therapeutics Be in 3 Years? - Nasdaq
1 Beaten-Down Stock to Buy and Hold for 10 Years - Yahoo Finance
BlackRock, Inc. Reduces Stake in Viking Therapeutics Inc - GuruFocus
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain - Nasdaq
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Why Viking Therapeutics Stock Popped Again Today - MSN
VKTX Stock Surges Amid Analyst Optimism on VK2735 - GuruFocus
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight By Investing.com - Investing.com India
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight - Investing.com
Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Why Viking Therapeutics (VKTX) Stock is On the Move - GuruFocus
Viking Therapeutics (VKTX) Sees Stock Rise Despite Increased Los - GuruFocus
Viking Therapeutics (VKTX) Gains Overweight Rating from Cantor F - GuruFocus
Why Viking Therapeutics Stock Popped Today - MSN
Viking Therapeutics (VKTX) Price Target Reduced Amid Competitive Obesity Market | VKTX Stock News - GuruFocus
Viking Therapeutics price target lowered to $75 from $95 at Truist - TipRanks
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - MSN
Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising results - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus - Investing.com
Viking Therapeutics Stock May Struggle After As-Expected Report - MarketBeat
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025 - simplywall.st
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):